<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="308180">
  <stage>Registered</stage>
  <submitdate>9/11/2009</submitdate>
  <approvaldate>12/11/2009</approvaldate>
  <actrnumber>ACTRN12609000977279</actrnumber>
  <trial_identification>
    <studytitle>Statins as an anti-inflammatory in asthma</studytitle>
    <scientifictitle>Statins as an effective anti-inflammatory therapy against diet-induced neutrophilic asthma</scientifictitle>
    <utrn />
    <trialacronym>SAIL Study (Statins Asthma Inflammation and Lipids)</trialacronym>
    <secondaryid>Nil known</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Asthma</healthcondition>
    <conditioncode>
      <conditioncode1>Respiratory</conditioncode1>
      <conditioncode2>Asthma</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>High fat challenge before and after Oral Simvastatin 40mg (1 tablet daily for 1 month)</interventions>
    <comparator>High fat challenge before and after Oral Simvastatin Placebo equivalent 40mg (inactive) containing lactose, 1 tablet daily for 1 month</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Postprandial change in sputum neutrophils</outcome>
      <timepoint>4 weeks following randomisation</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Postprandial change in Interleukin 6 (IL-6) from blood analysis</outcome>
      <timepoint>4 weeks following randomisation</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Stable asthma (with or without neutrophilic asthma)
Body Mass Index (BMI) &lt; 30</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>0</inclusivemaxage>
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>Current smokers,
Currently taking lipid lowering drugs or drugs that interact with statins.
Subjects with active liver disease, renal impairment, cardiovascular disease, pregnant or breastfeeding</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment>Following Informed Consent and screening for eligibilty for the study, subjects will be allocated a randomisation number. The allocation of the randomisation number will be done by the study co-ordinator sequencially, who will be unaware which group the subject will be allocated (active or placebo). The subject will then be given a container with the randomisation number attached. The generation of the randomisation schedule and the labelling of the study container will be carried out be independent persons not directly involved with the study subjects and concealed from the study staff.</concealment>
    <sequence>Randomisation will be performed by using a randomisation table created by a computer software program. Therefore computerised sequence generation.</sequence>
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint>Efficacy</endpoint>
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 3</phase>
    <anticipatedstartdate>9/11/2009</anticipatedstartdate>
    <actualstartdate>17/12/2009</actualstartdate>
    <anticipatedenddate />
    <actualenddate>8/06/2012</actualenddate>
    <samplesize>66</samplesize>
    <actualsamplesize>36</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW</recruitmentstate>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Individual</primarysponsortype>
    <primarysponsorname>Dr Lisa Wood</primarysponsorname>
    <primarysponsoraddress>Respiratory Medicine John Hunter Hospital
Level 3, Hunter Medical Research Institute (HMRI)
Lookout Road
New Lambton Heights NSW 2305</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Government body</fundingtype>
      <fundingname>National Health and Medical Research Council</fundingname>
      <fundingaddress>Director, Research Administration Section, GPO Box 1421, Canberra ACT 2601</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>University</sponsortype>
      <sponsorname>University of Newcastle</sponsorname>
      <sponsoraddress>University Drive
Callaghan NSW 2308</sponsoraddress>
      <sponsorcountry>Australia</sponsorcountry>
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will investigate a possible therapeutic strategy to modify diet-induced airway inflammation by the use of statins. The regular intake of high fat food directly causes systemic inflammation. This systemic inflammation may lead to asthma or contribute to increased airway inflammation seen in asthma. Statins are a widely prescribed class of cholesterol lowering drugs indicated for the prevention of cardiovascular disease. They have also be shown to reduce or inhibit inflammatory markers (C-Reactive Protein CRP, IL-6) and cytokines associated with innate immunity (Tumor Necrosis Factor-alpha TNF-alpha, Interleukin-8 IL-8). We propose that statins, which suppress the innate immune response, will suppress the neutrophilic inflammation that we expect as a consequence of a high fat diet.
Hypothesis: A high fat diet causes an increase in neutrophilic airway inflammation. Statins will protect against fat-induced inflammation in asthma.</summary>
    <trialwebsite />
    <publication>Wood LG, Garg ML, Gibson PG. A high fat challenge increases airway inflammation and impairs bronchodilator recovery in asthma. J Allergy Clin Immunol 2011 127(5):1133-40.</publication>
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname>Hunter New England Human Research Ethics Committee</ethicname>
      <ethicaddress>Lookout Road
New Lambton Heights NSW 2305</ethicaddress>
      <ethicapprovaldate>10/08/2009</ethicapprovaldate>
      <hrec>HNEHREC Reference No.: 09/07/15/3.05</hrec>
      <ethicsubmitdate>30/06/2009</ethicsubmitdate>
      <ethiccountry>Australia</ethiccountry>
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
AUSTRALIA</address>
      <phone>+61 2 4042 0147</phone>
      <fax>+61 2 4042 0046</fax>
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
AUSTRALIA
</address>
      <phone>+61240420147</phone>
      <fax>+61 2 40420046</fax>
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title>Dr</title>
      <name>Bronwyn Berthon</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
AUSTRALIA
</address>
      <phone>+ 61 2 40420116</phone>
      <fax>+61 2 4042 0046</fax>
      <email>bronwyn.berthon@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title>A/Prof</title>
      <name>Lisa Wood</name>
      <address>Centre for Asthma and Respiratory Diseases
Level 2, West Wing, HMRI Building
Kookaburra Crt
New Lambton Heights, NSW, 2305
AUSTRALIA
</address>
      <phone>+61240420147</phone>
      <fax>+61 2 4042 0046</fax>
      <email>lisa.wood@newcastle.edu.au</email>
      <country>Australia</country>
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>